Standard lymphodepletion regimen
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stiff-Person Syndrome
Conditions
Stiff-Person Syndrome, SPS
Trial Timeline
Sep 25, 2024 → Dec 1, 2026
NCT ID
NCT06588491About Standard lymphodepletion regimen
Standard lymphodepletion regimen is a phase 2 stage product being developed by Kyverna Therapeutics for Stiff-Person Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT06588491. Target conditions include Stiff-Person Syndrome, SPS.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06588491 | Phase 2 | Active |
Competing Products
1 competing product in Stiff-Person Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intravenous Immunoglobulins, Human + Placebos | Grifols | Phase 3 | 74 |
Other Products from Kyverna Therapeutics
Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101Phase 2/3
57
KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mABPhase 2
44
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapyPhase 1/2
33
KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimenPhase 1/2
33
KYV-101 + Standard lymphodepletion regimenPhase 1/2
33